Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: sintilimab|DRUG: bevacizumab biosimilar|DRUG: pegylated liposomal doxorubicin
Sponsor: Fudan University